Showing 3231-3240 of 4165 results for "".
- Alcon Unveils PRECISION7 1-Week Contact Lens with ACTIV-FLO Technologyhttps://modernod.com/news/alcon-unveils-precision7-one-week-contact-lens-with-activ-flo-technology/2482533/Alcon announced the US launch of PRECISION7, the first contact lens designed for a 1-week replacement cycle. Leveraging the 7-day ACTIV-FLO system, these lenses are designed to deliver up to 16 hours of exceptional comfort and clear vision, even on the seventh day of wear. [1]
- LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMDhttps://modernod.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd/2482525/The FDA has granted authorization to LumiThera allowing the company to market its Valeda Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to treat vision loss in patients with dry AMD.
- Corxel and Lenz Therapeutics Announce Positive Phase 3 Trial Results for Presbyopia Eye Drop LNZ100 in Chinahttps://modernod.com/news/corxel-pharmaceuticals-and-lenz-therapeutics-announce-positive-phase-3-trial-results-for-presbyopia-eye-drop-lnz100-in-china/2482519/Lenz Therapeutics and its parner Corxel Pharmaceuticals unveiled phase 3 trial results from the China-based JX07001 study, showing that LNZ100, an aceclidine-based eye drop, achieved significant improvement in near vision for presbyopia patients. The study's topline results demonstr
- Stanford University Study Finds Ovarian Cancer Drug Can Affect the Eyeshttps://modernod.com/news/stanford-university-study-finds-ovarian-cancer-drug-can-affect-the-eyes/2482510/A study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago found Mirvetuximab soravtansine (Elahere) is associated with corneal toxicity and related vision changes. Mirvetuximab is part of an emerging class of anti-cancer drugs called antibody-drug conjugates. A
- AAO: Home OCT Device Improves Care for AMD Patients, Reduces Costs and Burdenhttps://modernod.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/A newly approved home-based OCT device developed by Notel Vision is allowing patients to monitor their own eye health between appointments, providing physicians with crucial data without requiring in-office visits, according to an AAO news release. A study presented today at AAO 2024 suggest
- Hoya Highlights the Impact Rural vs Urban Living Environments May Have On Myopia In Young Childrenhttps://modernod.com/news/hoya-highlights-the-impact-rural-vs-urban-living-environments-may-have-on-myopia-in-young-children/2482457/Hoya Vision Care announced the results of a 5-year epidemiological study conducted in Scotland exploring the correlations between myopia, socio-economic deprivation, and urban or rural dwellings in young children. The study, which reviewed refractive error data from eye examinations in
- Staar Opens New Experience Center to Meet Growing Surgeon Demandhttps://modernod.com/news/staar-opens-new-experience-center-to-meet-growing-surgeon-demand/2482452/Staar Surgical announced the expansion of its Staar Surgical Experience Center near John Wayne Airport (SNA) in Lake Forest, California. The new center aims to provide comprehensive, hands-on training and education in lens-based vision correction. Staar says the 
- Ocutech Announces Release of SideSight Ultrasonic Sensor Device for Homonymous Hemianopiahttps://modernod.com/news/ocutech-announces-limited-release-of-sidesight-ultrasonic-sensor-device-for-homonymous-hemianopia/2482405/Ocutech announced the limited first release of its new ultrasonic sensor device, the SideSight. Developed in collaboration with experts in electrical, software, and mechanical engineering, Ocutech says the SideSight is designed to assist individuals who have experienced loss of side vision, a con
- Atsena Therapeutics Secures FDA Rare Pediatric Disease Designation for XLRS Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-fda-rare-pediatric-disease-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482398/The FDA has granted rare pediatric disease (RPD) designation for Atsena Therapeutics' gene therapy pruduct candidate ATSN-201, which is being examined to treat X-linked retinoschisis (XLRS). XLRS is a rare genetic disorder that leads to vision loss primarily in males.
- Lenz Therapeutics Submits NDA for LNZ100 Eye Drop for Presbyopiahttps://modernod.com/news/lenz-therapeutics-submits-new-drug-application-for-lnz100-eye-drop-for-presbyopia-treatment/2482397/Lenz Therapeutics has submitted a new drug application (NDA) to the FDA for LNZ100, an investigational presbyopia eye drop. This aceclidine-based ophthalmic solution is designed to improve near vision in people with presbyopia. The NDA submission follows the successful completion o